Ox-LDL R-1 Antibody (LOX19-22): sc-66155

Ox-LDL R-1 Antibody (LOX19-22) is a mouse monoclonal IgG1 kappa light chain antibody that detects the Ox-LDL R-1 protein of human origin by western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Anti-Ox-LDL R-1 antibody (LOX19-22) is available as a non-conjugated format. The oxidized low density lipoprotein (lectin-like) receptor-1, also known as Ox-LDL R-1, is a type II membrane protein belonging to the C-type lectin family, functioning as a critical cell-surface receptor for oxidized low density lipoprotein (Ox-LDL). Ox-LDL R-1 (LOX19-22) antibody recognizes a receptor that plays a significant role in atherosclerosis pathogenesis, particularly in transforming monocyte-derived macrophages into foam cells within atherosclerotic lesions. The interaction between Ox-LDL and Ox-LDL R-1 can activate the NFkB signaling pathway, which is pivotal in inflammatory responses. Ox-LDL R-1 is expressed in various cell types, including vascular endothelial cells, smooth muscle cells, and macrophages, and is initially synthesized as a precursor form with N-linked high mannose carbohydrate chains. N-linked glycosylation is essential for proper transport of Ox-LDL R-1 to the cell surface and efficient binding to ligands, thereby influencing receptor′s functional capacity in mediating cellular responses to oxidized lipoproteins.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Ox-LDL R-1 Antibody (LOX19-22) References:

1. Structure and chromosomal assignment of the human lectin-like oxidized low-density-lipoprotein receptor-1 (LOX-1) gene.  |  Aoyama, T., et al. 1999. Biochem J. 339 (Pt 1): 177-84. PMID: 10085242
2. Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions.  |  Kataoka, H., et al. 1999. Circulation. 99: 3110-7. PMID: 10377073
3. Scavenger receptors and oxidized low density lipoproteins.  |  Dhaliwal, BS. and Steinbrecher, UP. 1999. Clin Chim Acta. 286: 191-205. PMID: 10511292
4. Biosynthesis and post-translational processing of lectin-like oxidized low density lipoprotein receptor-1 (LOX-1). N-linked glycosylation affects cell-surface expression and ligand binding.  |  Kataoka, H., et al. 2000. J Biol Chem. 275: 6573-9. PMID: 10692464
5. Identification of soluble forms of lectin-like oxidized LDL receptor-1.  |  Murase, T., et al. 2000. Arterioscler Thromb Vasc Biol. 20: 715-20. PMID: 10712396
6. Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors.  |  Li, D. and Mehta, JL. 2000. Arterioscler Thromb Vasc Biol. 20: 1116-22. PMID: 10764682
7. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species.  |  Cominacini, L., et al. 2000. J Biol Chem. 275: 12633-8. PMID: 10777555
8. Transforming growth factor-beta(1) increases the expression of lectin-like oxidized low-density lipoprotein receptor-1.  |  Minami, M., et al. 2000. Biochem Biophys Res Commun. 272: 357-61. PMID: 10833418
9. LOX-1, OxLDL, and atherosclerosis.  |  Pirillo, A., et al. 2013. Mediators Inflamm. 2013: 152786. PMID: 23935243
10. Targeting lectin-like oxidized low-density lipoprotein receptor-1 triggers autophagic program in esophageal cancer.  |  Li, C., et al. 2022. Cell Death Differ. 29: 697-708. PMID: 34611296
11. Lectin-like oxidized low-density lipoprotein receptor 1 attenuates pneumonia-induced lung injury.  |  Korkmaz, FT., et al. 2022. JCI Insight. 7: PMID: 36264633
12. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1): a crucial driver of atherosclerotic cardiovascular disease.  |  Akhmedov, A., et al. 2021. Eur Heart J. 42: 1797-1807. PMID: 36282110

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Ox-LDL R-1 Antibody (LOX19-22) has 8 citations in a variety of scientific publications.

Primary antibodies like Anti-Ox-LDL R-1 Antibody (LOX19-22) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Ox-LDL R-1 Antibody (LOX19-22) Specifications

Alternate Product Name: OLR1

Product Clone Name: LOX19-22

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 58-273

Epitope Target: Ox-LDL R-1

Epitope Species: human

Product Reactivity/Detection: Ox-LDL R-1

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, ELISA

Vialing Information: Each vial contains 100 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 8 citations in various scientific publications

Available Conjugates/Forms for Ox-LDL R-1 Antibody (LOX19-22): N/A

The preferred Ox-LDL R-1 antibody is Ox-LDL R-1 Antibody (X-4): sc-80268.